Bortezomib - BioXcel

Drug Profile

Bortezomib - BioXcel

Alternative Names: BXCL 101

Latest Information Update: 11 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioXcel Corporation
  • Class Antineoplastics; Antirheumatics; Boronic acids; Pyrazines; Small molecules
  • Mechanism of Action Apoprotein stimulants; Immunomodulators; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neurofibromatosis 2
  • New Molecular Entity No
  • Available For Licensing Yes - Neurofibromatosis 2

Highest Development Phases

  • Clinical Phase Unknown Neurofibromatosis 2

Most Recent Events

  • 11 May 2017 Chemical structure information added
  • 17 Apr 2017 Bortezomib - BioXcel is available for licensing as of 17 Apr 2017. (BioXcel website, April 2017)
  • 13 Sep 2016 Clinical trials in Neurofibromatosis 2 in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top